<p>根据彭博社报道，摩根大通分析师将 Centessa Pharmaceuticals（纳斯达克股票代码：CNTA）的评级从&#34;持平&#34;调高至&#34;超配&#34;，并在周四向客户和投资者发布的研究报告中指出，该券商目前将该股票的目标价格定为 26.00 美元，高于之前的 11.00 美元。摩根大通的目标价格表明，该公司的股价有望比前一交易日上涨 64.04%。</p>
<p>其他分析师也发布了关于该股票的研究报告。Jefferies Financial Group 将 Centessa Pharmaceuticals 的目标股价从 13.00 美元上调至 19.00 美元，并在 9 月 11 日星期三的研究报告中给予该股票&#34;买入&#34;评级。BMO Capital Markets 将 Centessa Pharmaceuticals 的目标股价从 20.00 美元上调至 35.00 美元，并在周一的报告中给予该股票&#34;表现优异&#34;评级。B. Riley 在周四的一份研究报告中开始对 Centessa Pharmaceuticals 进行覆盖。他们给予该公司&#34;买入&#34;评级，并设定了 33.00 美元的目标股价。Guggenheim 将 Centessa Pharmaceuticals 的目标股价从 20.00 美元上调至 24.00 美元，并在 9 月 11 日星期三的研究报告中给予该股票&#34;买入&#34;评级。最后，Oppenheimer 在 8 月 14 日星期三的一份研究报告中重申了&#34;表现优异&#34;评级，并设定了 14.00 美元的目标股价。根据 MarketBeat.com 的数据，共有六位股票研究分析师对该股票给予了&#34;买入&#34;评级，Centessa Pharmaceuticals 目前的平均评级为&#34;买入&#34;，平均目标股价为 25.17 美元。</p>
<p><strong>查看我们关于 Centessa Pharmaceuticals 的最新报告</strong></p>
<h2>Centessa Pharmaceuticals 股价表现</h2>
<p>周四，纳斯达克股票代码为 CNTA 的股票上涨了 0.14 美元，报价为 15.85 美元。该公司的交易量为 811,734 股，相比平均交易量 388,219 股有所增加。该公司的流动比率为 13.29，速动比率为 13.29，负债权益比为 0.27。该公司的市值为 15.9 亿美元，市盈率为-11.16，贝塔系数为 1.44。Centessa Pharmaceuticals 的 52 周最低价为 5.15 美元，52 周最高价为 17.59 美元。该企业的 50 日移动平均价格为 12.15 美元，200 日移动平均价格为 10.60 美元。</p>
<p>Centessa Pharmaceuticals（纳斯达克股票代码：CNTA）于 8 月 13 日星期二发布了最新的财报。该公司报告称，该季度每股收益为-0.40 美元，低于分析师预期的-0.38 美元。作为一组，股票分析师预计 Centessa Pharmaceuticals 本财年的每股收益为-1.61 美元。</p>
<h2>Centessa Pharmaceuticals 内部交易</h2>
<p>根据其他 Centessa Pharmaceuticals 的消息，内部人员 Gregory M. Weinhoff 于 8 月 22 日星期四出售了 12,198 股公司股票。这些股票的平均价格为 12.17 美元，总交易额为 148,449.66 美元。交易完成后，该内部人员现在直接持有公司 241,171 股股票，价值 2,935,051.07 美元。该交易已在美国证券交易委员会的法律文件中披露，可通过此链接获得。此外，CEO Saurabh Saha 于 9 月 10 日星期二出售了 175,000 股股票。这些股票的平均价格为 16.52 美元，总价值为 2,891,000.00 美元。交易完成后，首席执行官现在持有公司 776,924 股股票，价值 12,834,784.48 美元。该交易已在美国证券交易委员会的申报文件中披露，可通过此超链接访问。此外，内部人员 Gregory M. Weinhoff 于 8 月 22 日星期四出售了 12,198 股公司股票。这些股票的平均价格为 12.17 美元，总交易额为 148,449.66 美元。交易完成后，该内部人员现在直接持有公司 241,171 股股票，价值 2,935,051.07 美元。有关此交易的披露信息可在此处找到。内部人员在过去三个月内共出售了价值 3,472,000 美元的公司股票，目前公司股份的 11.59% 由内部人员持有。</p>
<h2>机构投资者对 Centessa Pharmaceuticals 的看法</h2>
<p>对冲基金和其他机构投资者最近增加或减少了他们在该公司的持股。Nantahala Capital Management LLC 在第二季度购入了 Centessa Pharmaceuticals 的新头寸，价值约 4,064,000 美元。Perceptive Advisors LLC 在第二季度将其对 Centessa Pharmaceuticals 的持股增加了 27.6%。Perceptive Advisors LLC 现在拥有公司 3,933,307 股股票，价值 35,518,000 美元，比上一季度增加了 850,000 股。Quarry LP 在第二季度增持了 Centessa Pharmaceuticals 的股份，持股增长了 47.8%。Quarry LP 现在拥有公司 9,608 股股票，价值 87,000 美元，比上一季度增加了 3,108 股。Driehaus Capital Management LLC 在第二季度将其对 Centessa Pharmaceuticals 的持股增加了 89.5%。Driehaus Capital Management LLC 现在拥有公司 2,092,011 股股票，价值 18,891,000 美元，比上一季度增加了 987,997 股。最后，The Manufacturers Life Insurance Company 在第二季度将其对 Centessa Pharmaceuticals 的持股增加了 30.4%。The Manufacturers Life Insurance Company 现在拥有公司 140,894 股股票，价值 1,272,000 美元，比上一季度增加了 32,846 股。对冲基金和其他机构投资者拥有公司 82.01% 的股份。</p>
<h2>关于 Centessa Pharmaceuticals（获取免费报告）</h2>
<p>Centessa Pharmaceuticals plc 是一家临床阶段的制药公司，致力于发现、开发和提供药物给患者。其产品管线包括 SerpinPC，一种活化蛋白 C 抑制剂，目前正在 IIa 期临床开发，用于治疗血友病 A 和 B；以及 ORX750，一种口服 OX2R 激动剂，用于治疗 NT1，并有潜力扩展至其他睡眠障碍。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们比 Centessa Pharmaceuticals 更喜欢的股票</li>
<li>投资石油股的方法和原因</li>
<li>Edgewise Therapeutics 股价飙升 50%：涨势背后的关键原因</li>
<li>房地产投资信托在您的投资组合中应该占据什么位置？</li>
<li>联邦储备降息如何加速这 3 只 ETF 的增长</li>
<li>股票平均计算器</li>
<li>微软股票：它准备在第四季度大幅领先的 3 个原因</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ"/></p>
<p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ “我将为您提供所需的知识和信心，在五天或更短的时间内进行您的第一笔期权交易... 保证！”（来自 InvestorPlace）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NjEz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NjEz"/></p>
<h2>现在是否值得投资$1,000 在 Centessa Pharmaceuticals？</h2>
<p>在考虑 Centessa Pharmaceuticals 之前，您需要听到这个。</p>
<p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在购买的股票清单... 而 Centessa Pharmaceuticals 不在其中。</p>
<p>虽然 Centessa Pharmaceuticals 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

CNTA

<p>摩根大通（Morgan Stanley）将 Centessa Pharmaceuticals（纳斯达克股票代码：CNTA）的评级从 “持平” 调升至 “增持”，并将目标股价从$X.00 上调至$Y.00，显示潜在上涨空间为 64.04%。其他分析师，包括 Jefferies 和 BMO Capital Markets，也提高了他们的目标股价和评级。Centessa 的股价为$Z.85，市值为$A.59 十亿美元。最近的内部交易包括首席执行官 Saurabh Saha 和 Gregory M. Weinhoff 的大量股票销售。机构投资者也调整了他们在该公司的持股</p>

<p>Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) was upgraded by analysts at Morgan Stanley from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage presently has a $26.00 price objective on the stock, up from their prior price objective of $11.00. Morgan Stanley's target price points to a potential upside of 64.04% from the company's previous close.</p>
<div class="lb-trans"><p>根据彭博社报道，摩根大通分析师将 Centessa Pharmaceuticals（纳斯达克股票代码：CNTA）的评级从&#34;持平&#34;调高至&#34;超配&#34;，并在周四向客户和投资者发布的研究报告中指出，该券商目前将该股票的目标价格定为 26.00 美元，高于之前的 11.00 美元。摩根大通的目标价格表明，该公司的股价有望比前一交易日上涨 64.04%。</p>
</div><p>Other analysts have also issued research reports about the stock. Jefferies Financial Group raised their target price on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, September 11th. BMO Capital Markets raised their price objective on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an &#34;outperform&#34; rating in a report on Monday. B. Riley assumed coverage on Centessa Pharmaceuticals in a research note on Thursday. They issued a &#34;buy&#34; rating and a $33.00 target price for the company. Guggenheim raised their price target on Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, September 11th. Finally, Oppenheimer reaffirmed an &#34;outperform&#34; rating and set a $14.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Centessa Pharmaceuticals currently has an average rating of &#34;Buy&#34; and an average target price of $25.17.</p>
<div class="lb-trans"><p>其他分析师也发布了关于该股票的研究报告。Jefferies Financial Group 将 Centessa Pharmaceuticals 的目标股价从 13.00 美元上调至 19.00 美元，并在 9 月 11 日星期三的研究报告中给予该股票&#34;买入&#34;评级。BMO Capital Markets 将 Centessa Pharmaceuticals 的目标股价从 20.00 美元上调至 35.00 美元，并在周一的报告中给予该股票&#34;表现优异&#34;评级。B. Riley 在周四的一份研究报告中开始对 Centessa Pharmaceuticals 进行覆盖。他们给予该公司&#34;买入&#34;评级，并设定了 33.00 美元的目标股价。Guggenheim 将 Centessa Pharmaceuticals 的目标股价从 20.00 美元上调至 24.00 美元，并在 9 月 11 日星期三的研究报告中给予该股票&#34;买入&#34;评级。最后，Oppenheimer 在 8 月 14 日星期三的一份研究报告中重申了&#34;表现优异&#34;评级，并设定了 14.00 美元的目标股价。根据 MarketBeat.com 的数据，共有六位股票研究分析师对该股票给予了&#34;买入&#34;评级，Centessa Pharmaceuticals 目前的平均评级为&#34;买入&#34;，平均目标股价为 25.17 美元。</p>
</div><p><strong>View Our Latest Report on Centessa Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Centessa Pharmaceuticals 的最新报告</strong></p>
</div><h2>Centessa Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 股价表现</h2>
</div><p>Shares of NASDAQ:CNTA traded up $0.14 on Thursday, hitting $15.85. The company had a trading volume of 811,734 shares, compared to its average volume of 388,219. The company has a current ratio of 13.29, a quick ratio of 13.29 and a debt-to-equity ratio of 0.27. The company has a market cap of $1.59 billion, a PE ratio of -11.16 and a beta of 1.44. Centessa Pharmaceuticals has a 52-week low of $5.15 and a 52-week high of $17.59. The business has a 50 day moving average of $12.15 and a 200 day moving average of $10.60.</p>
<div class="lb-trans"><p>周四，纳斯达克股票代码为 CNTA 的股票上涨了 0.14 美元，报价为 15.85 美元。该公司的交易量为 811,734 股，相比平均交易量 388,219 股有所增加。该公司的流动比率为 13.29，速动比率为 13.29，负债权益比为 0.27。该公司的市值为 15.9 亿美元，市盈率为-11.16，贝塔系数为 1.44。Centessa Pharmaceuticals 的 52 周最低价为 5.15 美元，52 周最高价为 17.59 美元。该企业的 50 日移动平均价格为 12.15 美元，200 日移动平均价格为 10.60 美元。</p>
</div><p>Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). As a group, equities analysts anticipate that Centessa Pharmaceuticals will post -1.61 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals（纳斯达克股票代码：CNTA）于 8 月 13 日星期二发布了最新的财报。该公司报告称，该季度每股收益为-0.40 美元，低于分析师预期的-0.38 美元。作为一组，股票分析师预计 Centessa Pharmaceuticals 本财年的每股收益为-1.61 美元。</p>
</div><h2>Insider Transactions at Centessa Pharmaceuticals</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 内部交易</h2>
</div><p>In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 12,198 shares of the business's stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $12.17, for a total transaction of $148,449.66. Following the completion of the sale, the insider now directly owns 241,171 shares in the company, valued at $2,935,051.07. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 175,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $16.52, for a total value of $2,891,000.00. Following the completion of the sale, the chief executive officer now owns 776,924 shares of the company's stock, valued at $12,834,784.48. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, insider Gregory M. Weinhoff sold 12,198 shares of the business's stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $12.17, for a total transaction of $148,449.66. Following the transaction, the insider now directly owns 241,171 shares in the company, valued at $2,935,051.07. The disclosure for this sale can be found here. Insiders have sold a total of 216,873 shares of company stock worth $3,472,000 in the last three months. 11.59% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>根据其他 Centessa Pharmaceuticals 的消息，内部人员 Gregory M. Weinhoff 于 8 月 22 日星期四出售了 12,198 股公司股票。这些股票的平均价格为 12.17 美元，总交易额为 148,449.66 美元。交易完成后，该内部人员现在直接持有公司 241,171 股股票，价值 2,935,051.07 美元。该交易已在美国证券交易委员会的法律文件中披露，可通过此链接获得。此外，CEO Saurabh Saha 于 9 月 10 日星期二出售了 175,000 股股票。这些股票的平均价格为 16.52 美元，总价值为 2,891,000.00 美元。交易完成后，首席执行官现在持有公司 776,924 股股票，价值 12,834,784.48 美元。该交易已在美国证券交易委员会的申报文件中披露，可通过此超链接访问。此外，内部人员 Gregory M. Weinhoff 于 8 月 22 日星期四出售了 12,198 股公司股票。这些股票的平均价格为 12.17 美元，总交易额为 148,449.66 美元。交易完成后，该内部人员现在直接持有公司 241,171 股股票，价值 2,935,051.07 美元。有关此交易的披露信息可在此处找到。内部人员在过去三个月内共出售了价值 3,472,000 美元的公司股票，目前公司股份的 11.59% 由内部人员持有。</p>
</div><h2>Institutional Investors Weigh In On Centessa Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Centessa Pharmaceuticals 的看法</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC purchased a new position in Centessa Pharmaceuticals in the 2nd quarter valued at about $4,064,000. Perceptive Advisors LLC lifted its stake in shares of Centessa Pharmaceuticals by 27.6% in the second quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company's stock worth $35,518,000 after acquiring an additional 850,000 shares in the last quarter. Quarry LP boosted its holdings in Centessa Pharmaceuticals by 47.8% in the second quarter. Quarry LP now owns 9,608 shares of the company's stock valued at $87,000 after purchasing an additional 3,108 shares during the last quarter. Driehaus Capital Management LLC grew its stake in Centessa Pharmaceuticals by 89.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company's stock valued at $18,891,000 after purchasing an additional 987,997 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in Centessa Pharmaceuticals by 30.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 140,894 shares of the company's stock worth $1,272,000 after purchasing an additional 32,846 shares during the last quarter. Hedge funds and other institutional investors own 82.01% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近增加或减少了他们在该公司的持股。Nantahala Capital Management LLC 在第二季度购入了 Centessa Pharmaceuticals 的新头寸，价值约 4,064,000 美元。Perceptive Advisors LLC 在第二季度将其对 Centessa Pharmaceuticals 的持股增加了 27.6%。Perceptive Advisors LLC 现在拥有公司 3,933,307 股股票，价值 35,518,000 美元，比上一季度增加了 850,000 股。Quarry LP 在第二季度增持了 Centessa Pharmaceuticals 的股份，持股增长了 47.8%。Quarry LP 现在拥有公司 9,608 股股票，价值 87,000 美元，比上一季度增加了 3,108 股。Driehaus Capital Management LLC 在第二季度将其对 Centessa Pharmaceuticals 的持股增加了 89.5%。Driehaus Capital Management LLC 现在拥有公司 2,092,011 股股票，价值 18,891,000 美元，比上一季度增加了 987,997 股。最后，The Manufacturers Life Insurance Company 在第二季度将其对 Centessa Pharmaceuticals 的持股增加了 30.4%。The Manufacturers Life Insurance Company 现在拥有公司 140,894 股股票，价值 1,272,000 美元，比上一季度增加了 32,846 股。对冲基金和其他机构投资者拥有公司 82.01% 的股份。</p>
</div><h2>About Centessa Pharmaceuticals (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 Centessa Pharmaceuticals（获取免费报告）</h2>
</div><p>Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals plc 是一家临床阶段的制药公司，致力于发现、开发和提供药物给患者。其产品管线包括 SerpinPC，一种活化蛋白 C 抑制剂，目前正在 IIa 期临床开发，用于治疗血友病 A 和 B；以及 ORX750，一种口服 OX2R 激动剂，用于治疗 NT1，并有潜力扩展至其他睡眠障碍。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Centessa Pharmaceuticals</li>
<li>The How And Why of Investing in Oil Stocks</li>
<li>Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge</li>
<li>Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?</li>
<li>How the Fed’s Rate Cut Could Supercharge These 3 ETFs</li>
<li>Stock Average Calculator</li>
<li>Microsoft Stock: 3 Reasons It’s Ready to Crush Q4</li>
</ul>
<div class="lb-trans"><h2>精选文章</h2>
<ul>
<li>五只我们比 Centessa Pharmaceuticals 更喜欢的股票</li>
<li>投资石油股的方法和原因</li>
<li>Edgewise Therapeutics 股价飙升 50%：涨势背后的关键原因</li>
<li>房地产投资信托在您的投资组合中应该占据什么位置？</li>
<li>联邦储备降息如何加速这 3 只 ETF 的增长</li>
<li>股票平均计算器</li>
<li>微软股票：它准备在第四季度大幅领先的 3 个原因</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CNTA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ “I’ll Give You the Knowledge and Confidence You Need to Make Your First Options Trade in Five Days or Less… Guaranteed!” (From InvestorPlace)(Ad)</p>
<div class="lb-trans"><p>→ “我将为您提供所需的知识和信心，在五天或更短的时间内进行您的第一笔期权交易... 保证！”（来自 InvestorPlace）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NjEz" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9613&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Centessa Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资$1,000 在 Centessa Pharmaceuticals？</h2>
</div><p>Before you consider Centessa Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Centessa Pharmaceuticals 之前，您需要听到这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在购买的股票清单... 而 Centessa Pharmaceuticals 不在其中。</p>
</div><p>While Centessa Pharmaceuticals currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Centessa Pharmaceuticals 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Centessa Pharmaceuticals（纳斯达克股票代码：CNTA）被摩根士丹利上调至 “增持” 评级